Accelerated radiotherapy regimen for malignant gliomas using stereotactic concomitant boosts for dose escalation

Robert M. Cardinale, Rupert K. Schmidt-Ullrich, Stanley H Benedict, Robert D. Zwicker, Daniel C. Han, William C. Broaddus

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The purpose of this pilot study was to determine the feasibility and toxicities of an accelerated treatment program by using a concomitant stereotactic radiotherapy boost given weekly during a course of standard external-beam irradiation (EBXRT) in patients with malignant gliomas. Twelve patients underwent biopsy or subtotal resection of a malignant glioma and were enrolled on the protocol, which delivered 44 Gy-EBXRT and a 12-Gy stereotactic radiotherapy boost given on 3 consecutive weeks of treatment for a total dose of 80 Gy over 33 days. Three patients with anaplastic astrocytoma and nine patients with glioblastoma multiforme had median survival times of 33 months and 16 months, respectively. All of the tumor recurrences were within or were closely adjacent to the region of high-dose irradiation. None of the patients required a treatment break, and there were no acute complications. Two patients developed seizures in the follow-up period, and four patients were diagnosed with radionecrosis at the time of the second operation. The treatment program was found to be feasible and was well tolerated, and it resulted in a rate of late complications similar to those of radiosurgery or interstitial brachytherapy.

Original languageEnglish (US)
Pages (from-to)175-181
Number of pages7
JournalRadiation Oncology Investigations
Volume6
Issue number4
DOIs
StatePublished - 1998
Externally publishedYes

Fingerprint

acceleration (physics)
Glioma
radiation therapy
Radiotherapy
dosage
seizures
irradiation
Radiosurgery
Astrocytoma
Brachytherapy
Therapeutics
Glioblastoma
toxicity
interstitials
Seizures
tumors
Biopsy
Recurrence
Survival
Neoplasms

Keywords

  • Astrocytoma
  • Glioblastoma
  • Radiosurgery
  • Stereotactic

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology
  • Radiation

Cite this

Accelerated radiotherapy regimen for malignant gliomas using stereotactic concomitant boosts for dose escalation. / Cardinale, Robert M.; Schmidt-Ullrich, Rupert K.; Benedict, Stanley H; Zwicker, Robert D.; Han, Daniel C.; Broaddus, William C.

In: Radiation Oncology Investigations, Vol. 6, No. 4, 1998, p. 175-181.

Research output: Contribution to journalArticle

Cardinale, Robert M. ; Schmidt-Ullrich, Rupert K. ; Benedict, Stanley H ; Zwicker, Robert D. ; Han, Daniel C. ; Broaddus, William C. / Accelerated radiotherapy regimen for malignant gliomas using stereotactic concomitant boosts for dose escalation. In: Radiation Oncology Investigations. 1998 ; Vol. 6, No. 4. pp. 175-181.
@article{5383ec314dd44f49a41432fc51c32e46,
title = "Accelerated radiotherapy regimen for malignant gliomas using stereotactic concomitant boosts for dose escalation",
abstract = "The purpose of this pilot study was to determine the feasibility and toxicities of an accelerated treatment program by using a concomitant stereotactic radiotherapy boost given weekly during a course of standard external-beam irradiation (EBXRT) in patients with malignant gliomas. Twelve patients underwent biopsy or subtotal resection of a malignant glioma and were enrolled on the protocol, which delivered 44 Gy-EBXRT and a 12-Gy stereotactic radiotherapy boost given on 3 consecutive weeks of treatment for a total dose of 80 Gy over 33 days. Three patients with anaplastic astrocytoma and nine patients with glioblastoma multiforme had median survival times of 33 months and 16 months, respectively. All of the tumor recurrences were within or were closely adjacent to the region of high-dose irradiation. None of the patients required a treatment break, and there were no acute complications. Two patients developed seizures in the follow-up period, and four patients were diagnosed with radionecrosis at the time of the second operation. The treatment program was found to be feasible and was well tolerated, and it resulted in a rate of late complications similar to those of radiosurgery or interstitial brachytherapy.",
keywords = "Astrocytoma, Glioblastoma, Radiosurgery, Stereotactic",
author = "Cardinale, {Robert M.} and Schmidt-Ullrich, {Rupert K.} and Benedict, {Stanley H} and Zwicker, {Robert D.} and Han, {Daniel C.} and Broaddus, {William C.}",
year = "1998",
doi = "10.1002/(SICI)1520-6823(1998)6:4<175::AID-ROI5>3.0.CO;2-V",
language = "English (US)",
volume = "6",
pages = "175--181",
journal = "Radiation Oncology Investigations",
issn = "1065-7541",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Accelerated radiotherapy regimen for malignant gliomas using stereotactic concomitant boosts for dose escalation

AU - Cardinale, Robert M.

AU - Schmidt-Ullrich, Rupert K.

AU - Benedict, Stanley H

AU - Zwicker, Robert D.

AU - Han, Daniel C.

AU - Broaddus, William C.

PY - 1998

Y1 - 1998

N2 - The purpose of this pilot study was to determine the feasibility and toxicities of an accelerated treatment program by using a concomitant stereotactic radiotherapy boost given weekly during a course of standard external-beam irradiation (EBXRT) in patients with malignant gliomas. Twelve patients underwent biopsy or subtotal resection of a malignant glioma and were enrolled on the protocol, which delivered 44 Gy-EBXRT and a 12-Gy stereotactic radiotherapy boost given on 3 consecutive weeks of treatment for a total dose of 80 Gy over 33 days. Three patients with anaplastic astrocytoma and nine patients with glioblastoma multiforme had median survival times of 33 months and 16 months, respectively. All of the tumor recurrences were within or were closely adjacent to the region of high-dose irradiation. None of the patients required a treatment break, and there were no acute complications. Two patients developed seizures in the follow-up period, and four patients were diagnosed with radionecrosis at the time of the second operation. The treatment program was found to be feasible and was well tolerated, and it resulted in a rate of late complications similar to those of radiosurgery or interstitial brachytherapy.

AB - The purpose of this pilot study was to determine the feasibility and toxicities of an accelerated treatment program by using a concomitant stereotactic radiotherapy boost given weekly during a course of standard external-beam irradiation (EBXRT) in patients with malignant gliomas. Twelve patients underwent biopsy or subtotal resection of a malignant glioma and were enrolled on the protocol, which delivered 44 Gy-EBXRT and a 12-Gy stereotactic radiotherapy boost given on 3 consecutive weeks of treatment for a total dose of 80 Gy over 33 days. Three patients with anaplastic astrocytoma and nine patients with glioblastoma multiforme had median survival times of 33 months and 16 months, respectively. All of the tumor recurrences were within or were closely adjacent to the region of high-dose irradiation. None of the patients required a treatment break, and there were no acute complications. Two patients developed seizures in the follow-up period, and four patients were diagnosed with radionecrosis at the time of the second operation. The treatment program was found to be feasible and was well tolerated, and it resulted in a rate of late complications similar to those of radiosurgery or interstitial brachytherapy.

KW - Astrocytoma

KW - Glioblastoma

KW - Radiosurgery

KW - Stereotactic

UR - http://www.scopus.com/inward/record.url?scp=0031928470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031928470&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1520-6823(1998)6:4<175::AID-ROI5>3.0.CO;2-V

DO - 10.1002/(SICI)1520-6823(1998)6:4<175::AID-ROI5>3.0.CO;2-V

M3 - Article

C2 - 9727877

AN - SCOPUS:0031928470

VL - 6

SP - 175

EP - 181

JO - Radiation Oncology Investigations

JF - Radiation Oncology Investigations

SN - 1065-7541

IS - 4

ER -